➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
McKesson
Medtronic
Merck

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

CAMPATH Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for CAMPATH

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2
National Cancer Institute (NCI)Phase 1
M.D. Anderson Cancer CenterPhase 1

See all CAMPATH clinical trials

Recent Litigation for CAMPATH

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
AMGEN INC v. SANDOZ INC.2018-06-26

See all CAMPATH litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-01-08
2017-12-20

See all CAMPATH litigation

Pharmacology for CAMPATH

Company Disclosures: US Patents for CAMPATH

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2014-08-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for CAMPATH

These patents were identified by searching patent claims

Supplementary Protection Certificates for CAMPATH

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300816 Netherlands   Start Trial PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916
C02649086/01 Switzerland   Start Trial PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66778 18.10.2018
PA2019502 Lithuania   Start Trial PRODUCT NAME: TISAGENLEKLEUCELAS; REGISTRATION NO/DATE: EU/1/18/1297 20180823
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Merck
Baxter
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.